title: Mechanism of Roux-en-Y gastric bypass treatment for type 2 diabetes in rats.
abstract: OBJECTIVE
  Roux-en-Y gastric bypass (RYGB) is a novel therapy for diabetes. We aimed to explore the therapeutic mechanism of RYGB.
  
  
  METHODS
  After RYGB, animal models were established, and gene expression profile of islets was assessed. Additionally, gastrointestinal hormones were measured using enzyme-linked immunosorbent assays. Ca(2+) was studied using confocal microscopy and patch-clamp technique. The morphology of islets and beta cells was observed using optical microscopy and electron microscopy.
  
  
  RESULTS
  RYGB was an effective treatment in diabetic rats. Expression profiling data showed that RYGB produced a new metabolic environment and that gene expression changed to adapt to the new environment. The differential expression of genes associated with hormones, Ca(2+) and cellular proliferation was closely related to RYGB and diabetes metabolism. Furthermore, the data verified that RYGB led to changes in hormone level and enhanced Ca(2+) concentration changes and Ca(2+) channel activity. Morphological data showed that RYGB induced the proliferation of islets and improved the function of beta cells.
  
  
  CONCLUSIONS
  RYGB promoted a new metabolic environment while triggering changes to adapt to the new environment. These changes promoted the cellular proliferation of islets and improved the function of beta cells. The quantity of beta cells increased, and their quality improved, ultimately leading to insulin secretion enhancement.
authors.affiliation: School of Medicine, Tsinghua University, Beijing, People's Republic of China.
authors.forename: Hongwei
authors.initials: H
authors.lastname: Yu
authors.forename: Xiyan
authors.initials: X
authors.lastname: Zheng
authors.forename: Zongming
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000378:metabolism; D049109:Cell Proliferation; D002478:Cells, Cultured; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000378:metabolism* / Q000601:surgery*; D015390:Gastric Bypass; D054439:Ghrelin / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000378:metabolism* / Q000473:pathology; D007515:Islets of Langerhans / Q000378:metabolism* / Q000473:pathology; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D012313:RNA / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D059467:Transcriptome
chemical_list: D015220:Calcium Channels; D054439:Ghrelin; D007328:Insulin; D012313:RNA; D052216:Glucagon-Like Peptide 1; D002118:Calcium